Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Recursion licenses TxFM RNA foundation model to Tempus AI for oncology use in USD 12 million deal

Recursion licenses TxFM RNA foundation model to Tempus AI for oncology use in USD 12 million deal

BitgetBitget2026/09/21 16:18
  • Recursion Pharmaceuticals expanded its data partnership with Tempus AI, extending the term to six years from the effective date.
  • Revised annual license fees set at USD 14 million on each of the third, fourth, and fifth anniversaries, with at least USD 4 million paid in cash.
  • Removed Recursion’s right to terminate for convenience; reduced the total unique de-identified records it can access over the term.
  • Separate two-year oncology license grants Tempus use of Recursion’s TxFM RNA model; Tempus to pay USD 12 million in two installments.
  • Tempus to provide access to de-identified pathology records with linked clinical data during the TxFM license term.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001601830-26-000112), on September 21, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"

Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.

华尔街见闻•2026/11/07 07:31
Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"

SpaceX (SPCX.US) undergoes board changes: Google executive departs, Tesla merger evaluation underway.

SpaceX (SPCX.US) announced on Friday that Don Harrison has resigned from the company's board of directors.

智通财经•2026/11/07 06:31